The prevalence of the use of hair dye, a mixture of chemical compounds used to treat hair for cosmetic purposes, has increased worldwide, with an estimated 50–80 percent of women in the United States, Japan, and European Union reporting to have used hair dye in their lifetime [1]. Globally, the cosmetic manufacturing industry reported $255 billion in revenue in 2014, with hair care products accounting for nearly a quarter of industry revenue [2].

Hair dye products include a range of over 5000 chemical compounds and are composed of dye intermediates and dye couplers that interact with each other in the presence of hydrogen peroxide to form pigment molecules [3, 4]. Aromatic amines, such as para-phenylenediamine, are present in many hair dye products in order to impart hair color and prevent fading due to washing [5, 6]. At certain doses, some aromatic amines have been shown to be carcinogenic in animals and to significantly induce cytotoxic and genotoxic effects in human cells [6–10]. The primary carcinogenic mechanism of action is believed to involve CYP-450-mediated oxidation of parent aromatic amines to a carcinogenic metabolite [5]. It seems reasonable to assume that metabolic activation and subsequent genotoxic effects could occur in any tissue where reactive metabolites of aromatic amines accumulate to a significant degree, yet to date, bladder cancer appears to be the only cancer endpoint that is consistently increased in humans exposed to elevated levels of these compounds [11–13]. The International Agency for Research on Cancer (IARC) recently concluded that aromatic amine dyes are “probably carcinogenic” in hairdressers and barbers, based on “limited evidence” of an increased bladder cancer risk in the underlying epidemiology studies [1].

The association between personal use of hair dye (involving self-application) and cancer endpoints has also been evaluated, and inconsistent findings have been reported...
that vary by cancer type [14–16]. Takkouche et al. conducted a meta-analysis of the available data in 2005 and concluded that there was no “strong evidence of a marked increase in the risk of cancer among personal hair dye users,” but observed a “borderline” increased risk of hematopoietic cancers in the aggregated results of 40 studies (RR = 1.15; 95% CI, 1.05–1.27) [17]. Lymphocytic leukemia had one of the highest relative risks of all the hematopoietic disease endpoints evaluated (RR = 1.41; 95% CI, 1.06–1.88). More recently, IARC concluded that studies of personal hair dye users yielded inconclusive results and that personal hair dye use was therefore “not classifiable as to its carcinogenicity to humans” [1].

Leukemia, a type of hematopoietic cancer that arises in the bone marrow, is classified by the rate of growth (acute or chronic) and cell line of origin (lymphocytic or myeloid). According to the Surveillance, Epidemiology, and End Results Program (SEER), rates for new leukemia cases have been rising on average 0.3 percent per year over the last 10 years, with over 60,000 new cases of leukemia projected to occur in 2016 [18]. To our knowledge, aromatic amines have not been shown to be a cause of leukemia in animal studies or in occupational settings, yet as noted in the Takkouche analysis of personal hair dye users, “some aspects related to hematopoietic cancers should be investigated further” [17].

Since the meta-analysis of Takkouche in 2005, ten studies have been published in which the association between personal hair dye use and the risk of one or more leukemia subtypes was evaluated [3, 19–28]. Many of these more recent studies provided more robust information on gender and hair dye use patterns, including hair dye type and time period/duration of use. The goal of this study was to perform a current meta-analysis of all peer-reviewed epidemiology studies that have reported leukemia-specific cancer risks among personal hair dye users. Stratified analyses were performed to assess risk factors.

Material and Methods

Literature searches

We followed standardized PRISMA protocol and performed a systematic literature review to estimate the pooled relative risk of leukemia among personal hair dye users. Studies were identified by electronic database searching of PubMed, Web of Science, and Embase from their respective inception dates, using the search terms “hair” and (“dye” or “color” or “colour”) and (“leukemia” or “leukaemia” or “myeloid” or “lymphocytic” or “myelogenous” or “lymphoblastic”). Findings were supplemented with references manually obtained from the search results. Furthermore, we systematically reviewed studies that cited the articles that met our inclusion criteria. The latest search was conducted in May 2017.

Study selection

Two independent individuals reviewed and screened the title and abstract results to identify potentially relevant articles (Fig. 1). Selection criteria for full article review included (1) data on personal hair dye use, (2) all types of leukemia or subtypes of leukemia studied, (3) cohort or case–control studies, (4) reported risk estimates and 95% confidence intervals (95% CI), or available data for the calculation of measures of association. We excluded occupational studies examining hairdressers, preleukemia health endpoints (i.e., essential thrombocytopenia and myelodysplastic syndromes), perinatal exposure to hair dye use, reviews, editorials, and articles not written in English. Additionally, studies reporting pooled risk estimates for both leukemia and general lymphoma endpoints grouped together were excluded, but studies reporting risk estimates for specifically the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) endpoint were included due to the similarity of diseases. For studies examining the same cohort, preference was given to the more comprehensive analysis with longer length of follow-up or greater number of cases. The Kappa statistic was used to assess inter-rater agreement, and any disagreements were resolved by consensus with all authors.

Data abstraction

Data on study design, study population, primary exposure, subexposure, health outcome, risk estimates, confidence intervals, country of study, time period of diagnoses, time period of hair dye use data, number of cases and controls, cohort size, participation rate, and adjusted covariates were collected for each article. Study-specific data were abstracted by one reviewer and assessed for quality control by an independent reviewer.

Data synthesis and analysis

Each study was critiqued and analyzed for validity of study design and completeness of information based on potential for confounding, participation rate, loss to follow-up, methodology of interviews or questionnaires, and selection protocol. Sensitivity analyses were performed to determine the effect of study exclusion.

Fixed-effect and random-effects (in the presence of heterogeneity [P < 0.05]) models were employed to estimate the pooled relative risk (meta-RR) of all types of leukemia among all hair dye type users with 95% CI, weighted by the inverse of the study variance. Stratified analyses were performed by leukemia group (lymphocytic
Personal Use of Hair Dyes and Risk of Leukemia

K. M. Towle et al.

and myeloid), leukemia subtype (AML [acute myeloid leukemia and acute nonlymphocytic leukemia], CLL [chronic lymphocytic leukemia and small lymphocytic lymphoma], and ALL [acute lymphocytic leukemia and lymphoblastic leukemia]), duration of hair dye use (≤10 years or ≥15 years), time period of hair dye use (pre-1980 and post-1980), dark hair dye (black, brown, brunette, or classified as dark in paper), light hair dye (blonde or classified as light in paper), use of permanent hair dye, and gender. In these analyses, gender-, type-, and time period-specific risk estimates were included in the models when studies reported separate measures of association by males and females, permanent and semi-permanent hair dyes, and decade of hair dye use. No hair dye use was used as the reference group, and a minimum of four studies were required per stratified analysis. Cochran’s Q test was used to examine study heterogeneity. Funnel plots (log relative risk and standard error) and Egger’s test were performed to assess the potential of publication bias. All statistical analyses were performed using Stata software, version 14.2.

Results

A total of 33 papers met the inclusion criteria for full paper review from the original 206 abstracts (Fig. 1). The Kappa statistic for inter-rater agreement was 0.84, which is indicative of very good agreement. Twenty-five papers underwent full data abstraction (Table 1), including 20 case–control and five cohort studies. Reviewed articles were published between 1985 and 2016, and contained information from various North American, European, and Asian countries, including Sweden (n = 2), Serbia (n = 1), China (n = 3), Denmark (n = 1), Italy (n = 4), Greece (n = 1), Spain (n = 1), United States (n = 7), and multiple countries (n = 5). The studies examined all leukemia types grouped together, as well as various subtypes of lymphocytic and myeloid leukemia.

Due to the presence of overlapping cohorts, Thun 1994 and Zhang 2008 were removed from the analyses, with preference given to the more comprehensive analyses of Altekruse 1999 and Slager 2014, respectively [24, 26, 29, 30]. Additionally, Mele 1995 was excluded, as it analyzed a subset of patients from the Mele 1994 study [31, 32]. Markowitz 1985 did not report 95% CI, and was therefore also excluded from this analysis [33]. Based on data completeness review, Bjork 2001 was excluded from the analysis due to crude exposure classifications, no adjustment for smoking, and hair dye use information obtained by next of kin interviews in 81 percent of cases and only 14 percent of controls, which could introduce bias to the calculated odds ratio [34]. Sensitivity analyses
Table 1. Abstracted data from selected studies.

| Author             | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment                                                                 |
|--------------------|------|--------------|---------------------------------|-------------------|----------|---------|---------------|--------------|--------------|-------------------------|----------------|---------------------------------------------------------------------------|
| Albin et al. [51]  | 2000 | Case-control | 333 cases; 351 controls         | 65 Ever           | AML      | 0.98    | 0.64          | 1.5          | 1976–1993    | Adults                  | Age, gender, and county |
| Altekruse et al. [30] | 1999 | Cohort       | 547,586                         | 207 Ever          | All leukemias | 1.1     | 0.9           | 1.3          | 1982–1994    | Women                   | Age, race, smoking, education, occupation, and self-reported exposure to X-ray or fluoroscopic examinations, radium, radioactive isotopes, coal tar/ asphalt, diesel exhaust, dyes, gasoline exhaust, pesticides, textiles, and dusts |
| Altekruse et al. [30] | 1999 | Cohort       | 453,302                         | 69 1–5 years      | All leukemias | 0.9     | 0.7           | 1.2          | 1982–1994    | Women                   | Age, race, smoking, education, occupation, and self-reported exposure to X-ray or fluoroscopic examinations, radium, radioactive isotopes, coal tar/ asphalt, diesel exhaust, dyes, gasoline exhaust, pesticides, textiles, and dusts |
| Altekruse et al. [30] | 1999 | Cohort       | 432,903                         | 78 10–19 years    | All leukemias | 1.2     | 0.9           | 1.5          | 1982–1994    | Women                   | Age, race, smoking, education, occupation, and self-reported exposure to X-ray or fluoroscopic examinations, radium, radioactive isotopes, coal tar/ asphalt, diesel exhaust, dyes, gasoline exhaust, pesticides, textiles, and dusts |
| Altekruse et al. [30] | 1999 | Cohort       | 409,085                         | 60 20 + years     | All leukemias | 1.3     | 1.1           | 1.7          | 1982–1994    | Women                   | Age, race, smoking, education, occupation, and self-reported exposure to X-ray or fluoroscopic examinations, radium, radioactive isotopes, coal tar/ asphalt, diesel exhaust, dyes, gasoline exhaust, pesticides, textiles, and dusts |
| Benavente et al. [19] | 2005 | Case-control | 577 cases; 616 controls         | 37 Ever           | CLL      | 2.3     | 1.1           | 4.7          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 113 cases; 520 controls         | 27 Before 1980    | CLL      | 3.5     | 1.5           | 7.8          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 96 cases; 525 controls          | 10 After 1980     | CLL      | 1.5     | 0.6           | 3.6          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 110 cases; 546 controls         | 24 Dark           | CLL      | 2.3     | 1.1           | 4.9          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 103 cases; 510 controls         | 17 Light          | CLL      | 2.9     | 1.3           | 6.8          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 121 cases; 589 controls         | 35 Permanent      | CLL      | 3.4     | 1.4           | 7.8          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 89 cases; 456 controls          | 3 Semi-permanent  | CLL      | 1.6     | 0.4           | 6.6          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 92 cases; 502 controls          | 6 1–10 years      | CLL      | 1.1     | 0.4           | 3            | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 98 cases; 481 controls          | 12 11–24 years    | CLL      | 3.2     | 1.3           | 8.2          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Benavente et al. [19] | 2005 | Case-control | 105 cases; 491 controls         | 19 ≥25 years      | CLL      | 3.7     | 1.5           | 8.9          | 1998–2002    | Adults                  | Pathology center, gender, age, and house ownership |
| Bjork et al. [34]   | 2001 | Case-control | 226 cases; 251 controls         | 25 Ever           | CML      | 0.35    | 0.18          | 0.68         | 1976–1993    | Adults                  | Gender, age, and county |
| Cantor et al. [52]  | 1988 | Case-control | 577 cases; 1245 controls        | 43 Ever           | All leukemias | 1.8     | 1.1           | 2.7          | 1980–1983    | Men                     | State of residence, and age |
| Cantor et al. [52]  | 1988 | Case-control | 143 cases; 1245 controls        | 7 Ever            | ANL      | 1.1     | 0.5           | 2.6          | 1980–1983    | Men                     | State of residence, and age |
| Cantor et al. [52]  | 1988 | Case-control | 243 cases; 1245 controls        | 14 Ever           | CLL      | 1.4     | 0.7           | 2.6          | 1980–1983    | Men                     | State of residence, and age |
| Cantor et al. [52]  | 1988 | Case-control | 51 cases; 1245 controls         | 5 Ever            | CML      | 2.2     | 0.7           | 6.2          | 1980–1983    | Men                     | State of residence, and age |
| Cantor et al. [52]  | 1988 | Case-control | 16 cases; 1245 controls         | 2 Ever            | ALL      | 2.9     | 0.4           | 13.8         | 1980–1983    | Men                     | State of residence, and age |
| de Sanjose et al. [3] | 2006 | Case-control | 407 cases; 2417 controls        | 127 Ever          | CLL      | 1.43    | 1.01          | 2.03         | 1998–2003    | Adults                  | Center, gender, educational level, home ownership, and age |
| Grodstein et al. [53] | 1994 | Cohort       | 99,067                          | 8 Ever            | CLL      | 0.6     | 0.3           | 1.5          | 1976–1990    | Women                   | Age                     |
| Grodstein et al. [53] | 1994 | Cohort       | 99,067                          | 8 Ever            | AM/CM/ML/ALL | 0.8     | 0.3           | 1.9          | 1976–1990    | Women                   | Age                     |

(Continued)
| Author            | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment                                           |
|-------------------|------|--------------|--------------------------------|-------------------|----------|---------|---------------|--------------|--------------|-------------------------|----------------|-----------|
| Karakosta et al.  | 2015 | Case-control | 171 cases; 175 controls       | 33 Ever           | CLL      | 0.99    | 0.57          | 1.71         | NR           | NR          | Adults                | Age, gender, ethnicity, area of residence, and family history of malignancy |
| Markovic-Denic et al. | 1995 | Case-control | 130 cases; 130 controls       | 11 Ever           | CLL      | 1.97    | 1.08          | 3.59         | 1989         | Adults                | Gender, age, place of residence, area of residence, and income |
| Markowitz et al.  | 1985 | Case-control | 101 cases; 101 controls       | NR                | Ever     | 3.1     | NR            | NR           | 1980–1982    | Adults                | Matched (unspecified) |
| Mele et al.       | 1994 | Case-control | 252 cases; 1161 controls      | NR                | Ever     | 1.2     | 0.4           | 4            | 1987–1990    | Men                    | Age, education, and residence |
| Author     | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment                                      |
|------------|------|--------------|---------------------------------|-------------------|----------|---------|---------------|--------------|--------------|-------------------------|----------------|-----------------------------------------------|
| Mele et al. [32] | 1995 | Case-control | 36 cases; 1161 controls          | NR                | Ever     | APL     | 1.5           | 0.6          | 3.7          | 1986–1990                | Adults          | Age, gender, education, and residence        |
| Mendelsohn et al. [21] | 2009 | Cohort | 29, 22, 24, 22, 21 | NR, 2, 4, 2, 1 | Ever, 1–2 years, 3–4 years, 5–9 years, ≥10 years | Leukemia | 0.68, 0.31, 1.05, 0.89 | 0.31, 0.07, 0.36, 0.12 | 1.51, 1.31, 4.56 | 1996–2000, 2000-2001, 2001-2005 | Women, Adults | Age, education, and smoking                  |
| Miligi et al. [54] | 1999 | Case-control | NR                       | NR                | Ever     | Leukemia | 0.9           | 0.7          | 1.3          | NR                      | Adults          | Age                                           |
| Miligi et al. [22] | 2005 | Case-control | NR                       | NR                | Permanent | Leukemia | 1.2           | 0.9          | 1.7          | NR                      | Men             | Age and smoking                               |
| Rauscher et al. [55] | 2004 | Case-control | 769 cases; 623 controls       | 185               | Ever     | Leukemia | 1.3           | 0.99         | 1.8          | 1986–1989                | Adults          | Age, race, gender, geographic region, and education |
| Author            | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment |
|-------------------|------|--------------|---------------------------------|-------------------|----------|---------|---------------|--------------|--------------|--------------------------|-----------------|------------|
| Sandler et al. [56] | 1993 | Case-control | 613 cases; 515 controls          | 29                | 5–14 years (permanent) | Leukemia | 1.5           | 0.78         | 2.7          |                          |                 |            |
|                   |      |              | 608 cases; 514 controls          | 24                | 5–14 years (semi-permanent) | Leukemia | 1.3           | 0.67         | 2.5          |                          |                 |            |
|                   |      |              | 623 cases; 516 controls          | 39                | ≥15 years (permanent)     | Leukemia | 1.9           | 1.1          | 3.6          |                          |                 |            |
|                   |      |              | 605 cases; 516 controls          | 21                | ≥15 years (semi-permanent) | Leukemia | 1             | 0.52         | 2            |                          |                 |            |
|                   |      |              | 604 cases; 522 controls          | 50                | Light (permanent)        | Leukemia | 1.8           | 1.1          | 3.1          |                          |                 |            |
|                   |      |              | 609 cases; 511 controls          | 25                | Dark (permanent)         | Leukemia | 1.6           | 0.78         | 3.2          |                          |                 |            |
|                   |      |              | 606 cases; 522 controls          | 22                | Light (semi-permanent)   | Leukemia | 0.79          | 0.42         | 1.5          |                          |                 |            |
|                   |      |              | 612 cases; 519 controls          | 28                | Dark (semi-permanent)    | Leukemia | 1.2           | 0.65         | 2.1          |                          |                 |            |
|                   |      |              | 629 cases; 522 controls          | 45                | Before 1970 (permanent)  | Leukemia | 1.7           | 0.98         | 3            |                          |                 |            |
|                   |      |              | 611 cases; 512 controls          | 27                | 1970–1979 (permanent)    | Leukemia | 1.6           | 0.83         | 3.1          |                          |                 |            |
|                   |      |              | 597 cases; 506 controls          | 13                | After 1970 (permanent)   | Leukemia | 1.2           | 0.51         | 2.9          |                          |                 |            |
|                   |      |              | 621 cases; 519 controls          | 37                | Before 1970 (permanent)  | Leukemia | 1.6           | 0.87         | 2.8          |                          |                 |            |
|                   |      |              | 603 cases; 515 controls          | 19                | 1970–1979 (semi-permanent) | Leukemia | 0.98         | 0.5          | 1.9          |                          |                 |            |
|                   |      |              | 589 cases; 508 controls          | 5                 | After 1979 (semi-permanent) | Leukemia | 0.41         | 0.14         | 1.2          |                          |                 |            |
|                   |      |              | 615 cases; 630 controls          | NR                | Ever                     | Leukemia | 1.5           | 1.1          | 2.1          |                          | NR              | Adults     |
|                   |      |              | NR                               | NR                | Permanent                 | Leukemia | 1.6           | 1            | 2.4          |                          |                 |            |
|                   |      |              | NR                               | NR                | Semi-permanent            | Leukemia | 1.4           | 0.9          | 2.1          |                          |                 |            |
|                   |      |              | NR                               | NR                | Temporary                 | Leukemia | 1.2           | 0.3          | 4            |                          |                 |            |
|                   |      |              | NR                               | NR                | ≥16 years                 | Leukemia | 2.6           | NR           | NR           |                          |                 |            |
| Skibola et al. [23] | 2014 | Case-control | 38 cases; 4680 controls          | 27                | Ever                     | ALL      | 1             | 0.48         | 2.11         | NR                        | NR              | Adults     |
|                   |      |              | 13 cases; 2100 controls          | 2                 | Temporary                 | ALL      | 2             | 0.36         | 11.02         |                          |                 |            |
|                   |      |              | 35 cases; 4245 controls          | 24                | Permanent                 | ALL      | 0.94          | 0.44         | 2.03         |                          |                 |            |
|                   |      |              | 22 cases; 2654 controls          | 11                | Light                    | ALL      | 1.39          | 0.57         | 3.34         |                          |                 |            |
|                   |      |              | 24 cases; 3523 controls          | 13                | Dark                     | ALL      | 0.82          | 0.35         | 1.89         |                          |                 |            |
|                   |      |              |                                  |                   |                          |          |               |              |              |                          |                 |            |

(Continued)
Table 1. Continued

| Author         | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome   | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment |
|----------------|------|--------------|---------------------------------|-------------------|----------|-----------|--------------|--------------|--------------|--------------------------|-----------------|------------|
|                |      |              | 23 cases; 2650 controls         | 12                | 1–8 years | ALL       | 0.83         | 0.34         | 2.02         |                          |                 |            |
|                |      |              | 19 cases; 2413 controls          | 8                 | 9–19 years | ALL       | 1.06         | 0.40         | 2.80         |                          |                 |            |
|                |      |              | 14 cases; 2491 controls          | 3                 | 20+ years  | ALL       | 0.7          | 0.18         | 2.71         |                          |                 |            |
|                |      |              | 16 cases; 2863 controls          | 5                 | Before 1980| ALL       | 1.07         | 0.33         | 3.5          |                          |                 |            |
|                |      |              | 30 cases; 2702 controls          | 19                | After 1980 | ALL       | 1.23         | 0.5          | 3            |                          |                 |            |
| Slager et al.  | 2014 | Case-control | 404 cases; 4122 controls        | 284               | Ever      | CLL/SLL   | 1.08         | 0.86         | 1.37         | Until 2011               | Adults          | Age, gender, race, and study |
|                |      |              |                                 | 14                | Temporary | CLL/SLL   | 0.74         | 0.41         | 1.34         |                          |                 |            |
|                |      |              |                                 | 379               | Permanent | CLL/SLL   | 1.16         | 0.91         | 1.48         |                          |                 |            |
|                |      |              |                                 | 218               | Light     | CLL/SLL   | 1.13         | 0.84         | 1.51         |                          |                 |            |
|                |      |              |                                 | 292               | Dark      | CLL/SLL   | 1.11         | 0.86         | 1.44         |                          |                 |            |
|                |      |              |                                 | 192               | 1–8 years | CLL/SLL   | 1            | 0.71         | 1.42         |                          |                 |            |
|                |      |              |                                 | 191               | 9–19 years | CLL/SLL   | 1.22         | 0.86         | 1.72         |                          |                 |            |
|                |      |              |                                 | 215               | ≥20 years  | CLL/SLL   | 1.26         | 0.92         | 1.73         |                          |                 |            |
|                |      |              |                                 | 247               | Before 1980| CLL/SLL   | 1.36         | 1            | 1.86         |                          |                 |            |
|                |      |              |                                 | 216               | After 1980 | CLL/SLL   | 1.06         | 0.76         | 1.46         |                          |                 |            |
| Thun et al.    | 1994 | Cohort       | 85 cases; 3621 controls         | 16                | Ever      | Lymphoid  | 0.77         | 0.44         | 1.35         | 1982–1989               | Women           | Age        |
|                |      |              |                                 | 74                | 1–9 years | Lymphoid  | 0.71         | 0.27         | 1.86         |                          |                 |            |
|                |      |              |                                 | 76                | 10–19 years| Lymphoid  | 0.91         | 0.4          | 2.08         |                          |                 |            |
|                |      |              |                                 | 73                | ≥20 years  | Lymphoid  | 0.67         | 0.24         | 1.86         |                          |                 |            |
|                |      |              |                                 | 198               | Ever      | Myeloid and| 0.93         | 0.67         | 1.3          |                          |                 |            |
|                |      |              |                                 |                   |           | Monocytic  |             |              |              |                          |                 |            |
|                |      |              |                                 |                   |           |           |             |              |              |                          |                 |            |
|                |      |              |                                 |                   |           |           |             |              |              |                          |                 |            |
|                |      |              |                                 |                   |           |           |             |              |              |                          |                 |            |

(Continued)
Table 1. Continued

| Author          | Year | Study Design | Total N (exposed and unexposed) | N (exposed cases) | Exposure | Outcome | Risk Estimate | Lower 95% CI | Upper 95% CI | Time Period of Diagnosis | Study Population | Adjustment                                                                 |
|-----------------|------|--------------|--------------------------------|------------------|----------|---------|---------------|-------------|-------------|------------------------|----------------|---------------------------------------------------------------------------|
| Vedel-Krogh et al. [25] | 2016 | Cohort       | 45                             | 5                | Ever     | Leukaemia | 0.40          | 0.16         | 1.02        | 1976–1978              | Women           | Age, birth year, BMI, smoking, alcohol, physical activity, marital status, education, income, systolic blood pressure, cholesterol, triglycerides, glucose, FEV1, and FEV1/FVC |
| Wong et al. [27] | 2009 | Case-control | 263 cases; 530 controls        | NR               | Ever     | AML      | 0.98          | 0.8          | 1.2         | 2003–2007              | Adults          | Age and gender                                                          |
| Wong et al. [28] | 2010 | Case-control | 15 cases; 56 controls           | NR               | Ever     | CLL/SLL  | 0.37          | 0.18         | 0.76        | 2003–2008              | Adults          | Age and gender                                                          |
| Zahm et al. [57] | 1992 | Case-control | 37 cases; 723 controls          | 3                | Ever     | CLL      | 1             | 0.2          | 3.8         | 1983–1986              | Men             | Age                                                                       |
| Zhang et al. [26] | 2008 | Case-control | 324 cases                      | 244              | Ever     | CLL/SLL  | 1.3           | 1            | 1.6         | 1988–2003              | Women           | Age, race, and study center                                               |
|                 |      |              | 243 cases                      | 163              | Permanent | CLL/SLL  | 1.2           | 0.9          | 1.6         |                        |                 |                                                                           |
|                 |      |              | 181 cases                      | 101              | Nonpermanent | CLL/SLL  | 1.3           | 0.9          | 1.7         |                        |                 |                                                                           |
|                 |      |              | 228 cases                      | 148              | Dark     | CLL/SLL  | 1.2           | 0.9          | 1.7         |                        |                 |                                                                           |
|                 |      |              | 184 cases                      | 104              | Light    | CLL/SLL  | 1.3           | 0.9          | 1.8         |                        |                 |                                                                           |
|                 |      |              | 239 cases                      | 159              | Before 1980 | CLL/SLL  | 1.5           | 1.1          | 2          |                        |                 |                                                                           |
|                 |      |              | 164 cases                      | 84               | After 1980 | CLL/SLL  | 1.3           | 1            | 1.7         |                        |                 |                                                                           |
|                 |      |              | NR                            | NR               | ≥20 years | CLL/SLL  | 1.3           | 1            | 1.8         |                        |                 |                                                                           |

AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; NR, not reported.
indicated that the conclusions did not significantly change when Bjork was included in the model.

Based on 20 studies, ever use of any type of personal hair dye was associated with a nonstatistically significant increased risk of leukemia, when compared to no use of hair dye, meta-RR = 1.09 (95% CI: 0.97–1.22) (Fig. 2). A model restricted to case–control studies yielded a statistically significant increased meta-RR of 1.13 (95% CI: 1.00–1.28), while a model including cohort studies yielded a meta-RR of 1.00 (95% CI: 0.85–1.19) (Table 2). When restricted to studies that adjusted for smoking history, use of any hair dye was not associated with leukemia, meta-RR = 0.99 (95% CI: 0.76–1.29).

When stratified by subtype of leukemia, use of hair dye was associated with a statistically significant increased risk of lymphocytic leukemia (CLL, ALL, CLL/SLL, and lymphocytic endpoints), meta-RR = 1.17 (95% CI: 1.03–1.34), and a meta-RR = 1.06 (95% CI: 0.93–1.20) for myeloid leukemia (AML, CML, and myelocytic endpoints). No statistically significant associations were observed when models were separated by AML, CLL, and ALL subtypes individually (Table 2). Hair dye use among males was associated with a statistically significant increased risk of leukemia, meta-RR = 1.42 (95% CI: 1.01–2.00), while hair dye use among females was not, meta-RR = 1.02 (95% CI: 0.90–1.15).

Use of dark hair dye and permanent hair dye were both associated with a statistically significant increased risk of leukemia, meta-RR = 1.29 (95% CI: 1.11–1.50), and meta-RR = 1.19 (95% CI: 1.07–1.33), respectively, while the use of light hair dye, meta-RR = 1.13 (95% CI: 0.95–1.34), and semi-permanent or nonpermanent hair dye, meta-RR = 1.05 (95% CI: 0.86–1.29), were not. Additionally, use of hair dye prior to 1980 was associated with a statistically significant increased risk of leukemia, meta-RR = 1.49 (95% CI: 1.21–1.83), while use of hair dye after 1980 was not, meta-RR = 1.06 (95% CI: 0.81–1.38). Finally, use of hair dye for ≥15 years was associated with a statistically significant increased risk of leukemia, meta-RR = 1.35 (95% CI: 1.13–1.62), while use of hair dye for ≤10 years was associated with a meta-RR of 0.94 (95% CI: 0.80–1.11). A funnel plot and Egger's test did not show evidence of asymmetry (P = 0.53), and did not indicate the presence of publication bias (Fig. 3).

Discussion

Overview of findings

This analysis evaluated 25 studies published between 1985 and 2016 that reported leukemia-specific risk estimates among hair dye users. The majority of selected studies
reported relative risks by type of hair dye, duration/time period of use, gender, or leukemia subtype. A total of 149 individual risk estimates were considered in this analysis, 17 of which indicated a statistically significant increased risk of leukemia. When data from all studies were combined, we found that ever use of hair dye was associated with a nonstatistically significant increased risk of leukemia when compared to no use of hair dye. Findings also suggest that certain exposure characteristics, such as hair dye type (i.e., dark/permanent dye), time period of use (i.e., pre-1980), duration of use (i.e., ≥15 years), and male gender, are associated with a statistically significant increased risk of leukemia. However, the observed findings may be due to the introduction of bias and confounding by smoking, study design limitations, and historical formulations of hair dye products.

**Risk by any hair dye**

An unstratified meta-analysis indicated that use of any type of hair dye was associated with a nonstatistically significant increased risk of all types of leukemia, meta-RR 1.09 (95% CI: 0.97–1.22) (Table 2). This finding is in agreement with Takkouche [17] that reported a pooled RR of 1.12 (95% CI: 0.94–1.34) for all leukemia types and any dye users. The current analysis has tighter confidence intervals and included 10 case–control and two cohort studies not considered in the analysis performed by Takkouche.

Smoking is a suggested risk factor for the development of AML, ALL, and CML, potentially due to the presence of benzene, radioactive components, and other carcinogens present in tobacco and tobacco smoke [35–38]. The majority (15/20) of studies in this analysis did not directly control for smoking, and the studies that did control for smoking did not provide risk estimates by leukemia type. When restricted to studies that adjusted for smoking, the magnitude of the risk of leukemia decreased. This provides evidence of potential confounding by smoking if smoking histories differed among users and nonusers of hair dye. For example, an increased prevalence of smoking among hair dye users could result in an increased risk of leukemia, independent of hair dye use, and overestimate the true effect. Because so few studies controlled for smoking, we were unable to perform smoking-adjusted stratified analyses. This requires further research, as it remains unclear if adjustment for smoking would materially influence the observed outcomes in the stratified analyses.

Data from all studies combined suggest that hair dye use generally does not have a causal effect on the development of leukemia, potentially due to insufficient doses of chemicals present in hair dyes, or the ability of skin cells to detoxify aromatic amines and attenuate systemic exposure [39, 40]. Conversely, this crude unstratified meta-analysis may have diluted certain patterns of use that are associated with an increased risk of developing leukemia. Additionally, a significant amount of heterogeneity was observed in the unstratified model, likely due to the presence of various exposure classifications and study designs. Therefore, this study performed stratified meta-analyses by various exposure characteristics to understand the potential drivers of risk.

### Table 2. Meta-RR for leukemia among all models, comparing hair dye users to nonusers.

| Number of studies (n) | Meta-RR | 95% CI | Heterogeneity | P-value | I² (%) |
|-----------------------|---------|--------|---------------|---------|--------|
| Any dye use           | 20      | 1.09   | 0.97–1.22     | 0.014   | 41.4   |
| Any dye use (case–control) | 16     | 1.13   | 1.00–1.28     | 0.024   | 41.2   |
| Any dye use (cohort)   | 4       | 1.00   | 0.85–1.19     | 0.113   | 46.5   |
| Any dye use (smoking adjusted) | 5     | 0.99   | 0.76–1.29     | 0.037   | 57.9   |
| Dark hair dye          | 8       | 1.29   | 1.11–1.50     | 0.804   | 0      |
| Light hair dye         | 7       | 1.13   | 0.95–1.34     | 0.190   | 26.7   |
| Permanent hair dye     | 10      | 1.19   | 1.07–1.33     | 0.207   | 24.1   |
| Semi or non–permanent hair dye | 7     | 1.05   | 0.86–1.29     | 0.854   | 0      |
| Males                  | 4       | 1.42   | 1.01–2.00     | 0.204   | 32.6   |
| Females                | 7       | 1.02   | 0.90–1.15     | 0.517   | 0      |
| Pre–1980               | 4       | 1.49   | 1.21–1.83     | 0.361   | 8.9    |
| Post-1980              | 4       | 1.06   | 0.81–1.38     | 0.439   | 0      |
| Lymphocytic Leukemia   | 13      | 1.17   | 1.03–1.34     | 0.054   | 39.2   |
| Myeloid Leukemia       | 6       | 1.06   | 0.93–1.20     | 0.511   | 0      |
| Acute Myeloid Leukemia | 4       | 0.99   | 0.85–1.16     | 0.989   | 0      |
| Chronic Lymphocytic Leukemia | 10   | 1.15   | 0.90–1.46     | 0.020   | 51.4   |
| Acute Lymphocytic Leukemia | 4     | 1.29   | 0.93–1.78     | 0.485   | 0      |
| ≥15 years of use       | 5       | 1.35   | 1.13–1.62     | 0.149   | 38.5   |
| ≤10 years of use       | 7       | 0.94   | 0.80–1.11     | 0.869   | 0      |
When stratified by study type, ever use of hair dye was associated with a statistically significant increased risk of leukemia in case–control studies, which was not observed in cohort studies (Table 2). Hair dye use exposure was generally measured at baseline in cohort studies, which could introduce bias from exposure misclassification if hair dye use behaviors changed during follow-up. Specifically, nondifferential misclassification of binarily measured exposures would result in a bias in the risk estimate toward the null value, which could explain the observed reduction in the pooled risk estimate among cohort studies. Conversely, case–control studies are susceptible to recall bias if the reporting of exposures is systematically dissimilar between the cases and controls. Among case–control studies, if cases were more likely to report hair dye use exposures, then the pooled risk estimate would be biased away from the null and overestimate the true effect. It is therefore worth noting that (1) only case–control studies reported statistically significant increased risk estimates, and (2) the majority of studies included in the overall and subsequent stratified analyses were case–control studies.

Risk by hair dye type

Individuals who used dark-colored hair dye products were at a statistically significant increased risk of leukemia, whereas those that used light-colored hair dye products were not (Table 2). Dark hair dyes contain a higher concentration of primary aromatic amine intermediates and couplers in order to increase the shade of color [14]. Hence, there are more reactive chemical species in dark hair dyes, which could explain the color-based difference in leukemia risk. Also, users of permanent hair dye were at a statistically significant increased risk of all types of leukemia, which was not observed among semi-permanent or non-permanent hair dye users. This result differs from Takkouche [17], potentially due to the increased robustness of the underlying data in the current analysis. Permanent hair dyes undergo an oxidative reaction to impart color to the cortex of the hair shaft, which can result in oxidative damage [4]. Oxidative damage has been associated with DNA mutations and cell proliferation during cancer initiation and progression [41]. In contrast, semi-permanent or non-permanent hair dyes do not penetrate the hair cortex or undergo oxidative reactions, but rather utilize van der Waals forces to adhere to the hair cuticle [4, 15].

Risk by time period and duration of use

This study also examined time period of hair dye use as a driver of leukemia risk. During the 1970s, the cosmetic industry incorporated aromatic amine ingredients (including 2, 4-diaminoanisole, 2-amino-4-nitrophenol, and 2, 4-diaminotoluene) into hair dye formulations that were shown to produce mutagenic activity and dermally penetrate humans, resulting in regulatory action in 1978 to ban certain aromatic amine compounds in the European Union [6, 15, 42–45]. Additionally, in 1980, the Food and Drug Administration (FDA) required the presence of a warning label on hair dyes including 4-methoxy-m-phenylenediamine and 4-methyl-m-phenylenediamine sulfate, stating that the product “contains an ingredient that can penetrate your skin and has been determined to cause cancer in laboratory animals” [46].
The implication of these time-varying exposures is that hair dyes prior to reformulation are potentially more carcinogenic than more recent hair dye formulations after the removal of certain mutagenic ingredients. Specifically, this study found that individuals who used hair dye products prior to 1980 were at a statistically significant increased risk of leukemia, which was not observed in individuals that used hair dyes after 1980 (Table 2). All underlying studies were age-adjusted case-control designs, so these variables likely did not differentially influence the observed outcomes. Among studies that reported “ever” use of hair dye, we were unable to stratify the underlying risk estimates in a systematic way by pre- and post-1980 dye formulations. Therefore, the current observed increased risks among studies may be driven by historical hair dye constituents. However, it should also be noted that the lack of a statistically significant association for more recent post-1980 hair dye use may be due to insufficient induction and latency periods since first exposure, or reduced cumulative lifetime exposures.

This analysis also provided evidence that duration of use may be a factor in the risk of leukemia, as use of hair dye for ≥15 years was associated with an increased risk of leukemia, while use of hair dye for ≤10 years was associated with a decreased risk of leukemia (Table 2). All underlying studies adjusted for age. However, these findings could also be an artifact of prior formulations, as individuals using hair dyes for ≥15 years may have used hair dye products prior to 1980. Similar to the time period stratification analysis, lack of an increased risk for the ≤10 years group could be due to latency, which has been reported to range from 1.5 to 15 years for leukemia [47].

Risk by leukemia type and gender

Lymphocytic leukemia develops from lymphocytes while myeloid leukemia arises from primarily granulocytes or monocytes. Similar to Takkouche, we report that hair dye use was associated with an increased risk of lymphocytic leukemia (Table 2). This trend was also observed when further stratified by leukemia subtype, with hair dye use being associated with a higher magnitude of risk for ALL and CLL than AML. We were unable to perform a separate model for CML due to an insufficient number of studies. Research has suggested that lymphocyte cells may be susceptible to hair dye constituents, as it has been noted that DNA damage in lymphocytes was slightly higher in volunteers after hair dying, and that single-strand DNA breaks were produced in lymphocyte cells exposed to para-phenylenediamine [48, 49].

Findings also suggest that male users of hair dye are at an increased risk of leukemia, which is an area of research that requires further investigation. This may be due to different hair dye use exposure patterns (i.e., frequency of use, differences in dye types, etc.); however, as there were only four studies that provided male-specific risk estimates, we were unable to further stratify subanalyses by gender. It should be noted that all studies involving men were case-control studies.

Strengths and limitations

The main strength of this study is that it provides a pooled estimate of leukemia risk among hair dye users across various study populations. Additionally, the inclusion of more studies allowed for the further investigation of exposure characteristics, including hair dye type and duration/time period of use. A methodological limitation was less accurate exposure classification in studies that assessed the risk of leukemia due to a suite of past occupational and lifestyle exposures, and therefore only collected limited data on the history of lifetime hair dye use [20, 27, 28, 34, 50, 51]. Specifically, studies that only collected information on “ever” use of hair dye were unable to adequately characterize exposure profiles that may influence the risk of disease, as shown in the above stratified analyses.

This analysis is also limited by the studied disease classifications, with some studies reporting risk estimates for all leukemia types combined rather than by specific leukemia subtypes. The most informative summary risk measures should be analyzed by leukemia subtype due to different etiologies. However, we were unable to perform meta-analyses for all leukemia subtypes, and were unable to further stratify subtype meta-analyses by hair dye type, gender, etc. This body of literature would benefit from additional studies by specific leukemia subtypes. Additionally, the underlying studies did not provide data that enabled us to perform a robust dose-response analysis. While we used duration of use as a proxy of cumulative dose to assess the dose-response relationship, future studies should attempt to characterize different dose levels.

The issue of dependency also arises during the analysis of underlying case-control studies. In studies that calculated risk estimates for non-Hodgkin lymphoma, multiple myeloma, and leukemia, the same control populations were used in all calculations despite differing disease outcomes. Therefore, these calculations in the underlying studies may not be considered independent, and multiple comparisons may result in observed statistically significant associations that do not exist [52].

Conclusions

Findings suggest that personal hair dye use is not a significant risk factor for leukemia when data from all studies were combined. Additionally, statistically significant
associations were observed when studies were stratified by exposure profile characteristics, including hair dye type, gender, and duration/time period of use. While statistically significant, the clinical significance of these findings remains unclear. Further research is required to determine whether the aforementioned stratified associations truly reflect a risk of leukemia in certain users of hair dye, due to the potential for methodological limitations in the underlying studies (e.g., confounding and recall bias) to overestimate the true effect.

Conflict of Interest

The authors declare that there are no conflicts of interest. The authors are employed by Cardno ChemRisk, a consulting firm that provides scientific advice to the government, corporations, law firms, and various scientific/professional organizations. Cardno ChemRisk has not performed consulting work for hair dye manufacturers, and this analysis was designed, conducted, and funded exclusively by Cardno ChemRisk.

References

1. IARC. 2010. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 99. Some Aromatic Amines, Organic Dyes, and Related Exposures. IARC Press, Lyon.
2. Guenard, R. 2015. Hair dye: a history. The Atlantic
3. De Sanjóse, S., Y. Benavente, A. Nieters, L. Foretova, M. Maynadie, P. L. Cocco, et al. 2006. Association between personal use of hair dyes and lymphoid neoplasms in Europe. Am. J. Epidemiol. 164:47–55.
4. Kim, K.-H., E. Kabir, and S. A. Jahan. 2016. The use of personal hair dye and its implications for human health. Environ. Int. 89:222–227.
5. Stanley, L. A., J. A. Skare, E. Doyle, R. Powrie, D. D'Angelo, and C. R. Elcombe. 2005. Lack of evidence for metabolism of p-phenylenediamine by human hepatic cytochrome P450 enzymes. Toxicology 210:147–157.
6. Bolt, H. M., and K. Golka. 2007. The debate on carcinogenicity of permanent hair dyes: new insights. Crit. Rev. Toxicol. 37:521–536.
7. Sontag, J. M. 1981. Carcinogenicity of substituted-benzenediazines (phenylenediamines) in rats and mice. J. Natl Cancer Inst. 66:591–602.
8. Huang, Y.-C., W.-C. Hung, W.-Y. Kang, W.-T. Chen, and C.-Y. Chai. 2007. P Phenylenediamine induced DNA damage in SV-40 immortalized human uroepithelial cells and expression of mutant p53 and COX-2 proteins. Toxicol. Lett. 170:116–123.
9. Reena, K., K. Y. Ng, R. Y. Koh, P. Gnanajothy, and S. M. Chye. 2016. para-Phenylenediamine induces apoptosis through activation of reactive oxygen species-mediated mitochondrial pathway, and inhibition of the NF-κB, mTOR, and Wnt pathways in human urothelial cells. Environ. Toxicol. 32:265–277.
10. Tafurt-Cardona, Y., P. Suárez-Rocha, T. C. C. Fernandes, and M. A. M. Morales. 2015. Cytotoxic and genotoxic effects of two hair dyes used in the formulation of black color. Food Chem. Toxicol. 86:9–15.
11. Ol fert, S. M., S. A. Felknor, and G. L. Delclos. 2006. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures. South. Med. J. 99:1256–1264.
12. Clapp, R. W., M. M. Jacobs, and E. L. Loechler. 2008. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev. Environ. Health 23:1–38.
13. Cumberbatch, M. G., A. Cox, D. Teare, and J. W. F. Catto. 2015. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncology 1:1282–1290.
14. Rollison, D. E., K. J. Helzlsouer, and S. M. Pinney. 2006. Personal hair dye use and cancer: a systematic literature review and evaluation of exposure assessment in studies published since 1992. Journal of Toxicology and Environmental Health, Part B 9:413–439.
15. Saitta, P., C. E. Cook, J. L. Messina, R. Brancaccio, B. C. Wu, S. K. Grekin, et al. 2013. Is there a true concern regarding the use of hair dye and malignancy development? A review of the epidemiological evidence relating personal hair dye use to the risk of malignancy. J. Clin. Aesthet. Dermatol. 6:39.
16. Zhang, Y., C. Kim, and T. Zheng. 2011. Hair dye use and risk of human cancer. Front. Biosci. (Elite edition) 4:516–528.
17. Takkouche, B., M. Etminan, and A. Montes-Martinez. 2005. Personal use of hair dyes and risk of cancer: a meta-analysis. JAMA 293:2516–2525.
18. NCI. 2016. SEER Cancer Statistics Factsheets: Leukemia. National Cancer Institute Bethesda, MD, http://seer.cancer.gov/statfacts/html/leuks.html
19. Benavente, Y., N. Garcia, E. Domingo-Domenech, T. Alvaro, R. Font, Y. Zhang, et al. 2005. Regular use of hair dyes and risk of lymphoma in Spain. Int. J. Epidemiol. 34:1118–1122.
20. Karakosta, M., E.-M. Delicha, G. Kouraklis, and K. N. Manola. 2016. Association of various risk factors with chronic lymphocytic leukemia and its cytogenetic characteristics. Arch. Environ. Occup. Health 71:317–329.
21. Mendelsohn, J. B., Q. Z. Li, B. T. Ji, X. Shu, G. Yang, H. Li, et al. 2009. Personal use of hair dye and cancer risk in a prospective cohort of Chinese women. Cancer Sci. 100:1088–1091.
22. Miligi, L., A. S. Costantini, A. Benvenuti, A. Veraldi, R. Tumino, V. Ramazzotti, et al. 2005. Personal use of hair dyes and hematolymphopoietic malignancies. Arch. Environ. Occup. Health 60:249–256.
32. Mele, A., A. Stazi, A. Pulsoni, G. Visani, B. Monarca, G. Castelli, et al. 1993. Epidemiology of acute promyelocytic leukemia. Haematologica 80:405–408.
33. Markowitz, J., M. Szkel, L. Sensenbrenner, and S. Warm. 1985. Hair-dyes and acute nonlymphocytic leukemia. Am. J. Epidemiol. 122:523.
34. Björk, J., M. Albin, H. Welinder, H. Tinnerberg, N. Mauritzson, T. Kauppinen, et al. 2001. Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukemia? Occup. Environ. Med. 58:722–727.
35. Thomas, X., and Y. Chelghoum. 2004. Cigarette smoking and acute leukemia. Leukemia & Lymphoma 45:1103–1109.
36. Musselman, J. R., C. K. Blair, J. R. Cerhan, P. Nguyen, B. Hirsch, and J. A. Ross. 2013. Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol. 37:410–416.
37. Fircanis, S., P. Merriam, N. Khan, and J. J. Castillo. 2014. The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta-analysis of epidemiological studies. Am. J. Hematol. 89: E125–E132.
38. Sandler, D. P., D. L. Shore, J. R. Anderson, F. R. Davey, D. Arthur, R. J. Mayer, et al. 1993. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J. Natl Cancer Inst. 85:1994–2003.
39. Zeller, A. 2013. Pfühler S. N-acetylation of three aromatic amine hair dye precursor molecules eliminates their genotoxic potential. Mutagenesis 29:37–48.
40. Bonifas, J., and B. Blomeke. 2014. N-acetylation of aromatic amines: implication for skin and immune cells. Front Biosci (Elite edition) 7:267–281.
41. Reuter, S., S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal. 2010. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. 49:1603–1616.
42. Ames, B. N., H. Kammen, and E. Yamasaki. 1975. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc. Natl Acad. Sci. 72:2423–2427.
43. Wolfram, L., and H. Maibach. 1985. Percutaneous penetration of hair dyes. Arch. Dermatol. Res. 277:235–241.
44. Harling, M., A. Schablon, G. Schellbauer, M. Dulong, and A. Nienhaus. 2010. Bladder cancer among hairdressers: a meta-analysis. Occup. Environ. Med. 67:351–358.
45. Turati, F., C. Pelucchi, C. Galeone, A. Decarli, and C. La Vecchia. 2014. Personal hair dye use and bladder cancer: a meta-analysis. Ann. Epidemiol. 24:151–159.
46. FDA. 21CFR740.18. Coal Tar Hair Dyes Posing a Risk of Cancer. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfr/cfrsearch.cfm?fr=740.18. 2015. Accessed September 14, 2016.
47. Howard, J.. 2013. Minimum latency & types or categories of cancer. Replaces administrator's white paper on minimum latency & types of cancer. Centers for disease control and prevention.
48. Cho, J.-A., E. Oh, E. Lee, and D. Sul. 2003. Effects of hair dyeing on DNA damage in human lymphocytes. J Occup. Health 45:376–381.

49. Chye, S. M., Y. C. Hseu, S.-H. Liang, C.-H. Chen, and S. C. Chen. 2008. Single strand dna breaks in human lymphocytes exposed to para-phenylenediamine and its derivatives. Bull. Environ. Contam. Toxicol. 80:58–62.

50. Markovic-Denic, L., S. Jankovic, J. Marinkovic, and Z. Radovanovic. 1994. Brick mortar exposure and chronic lymphocytic leukemia. Neoplasma 42:79–81.

51. Albin, M., J. Björk, H. Welinder, H. Tinnerberg, N. Mauritzson, B. Johansson, et al. 2000. Acute myeloid leukemia and clonal chromosome aberrations in relation to past exposure to organic solvents. Scand. J. Work Environ. Health 26:482–491.

52. Cantor, K. P., A. Blair, G. Everett, S. VanLier, L. Burmeister, F. R. Dick, et al. 1988. Hair dye use and risk of leukemia and lymphoma. Am. J. Public Health 78:570–571.

53. Grodstein, F., C. H. Hennekens, G. A. Colditz, D. J. Hunter, and M. J. Stampfer. 1994. A prospective study of permanent hair dye use and hematopoietic cancer. J. Natl Cancer Inst. 86:1466–1470.

54. Miligi, L., A. S. Costantini, P. Crosignani, A. Fontana, G. Masala, O. Nanni, et al. 1999. Occupational, environmental, and life-style factors associated with the risk of hematolymphopoietic malignancies in women. Am. J. Ind. Med. 36:60–69.

55. Rauscher, G. H., D. Shore, and D. P. Sandler. 2004. Hair dye use and risk of adult acute leukemia. Am. J. Epidemiol. 160:19–25.

56. Sandler, D., D. Shore, and C. Bloomfield. 1993. Hair dye use and leukemia. Am. J. Epidemiol. 138:636–637.

57. Zahm, S. H., D. D. Weisenburger, P. A. Babbitt, R. C. Saal, J. B. Vaught, and A. Blair. 1992. Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Am. J. Public Health 82:990–997.